

Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

SECTION 1. IDENTIFICATION

Product name : Embutramide / Mebezonium / Tetracaine Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Flammable liquids : Category 4

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Acute toxicity (Dermal) : Category 4

Eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity

- single exposure

Category 2 (Nervous system, muscle)

Specific target organ toxicity

- single exposure

Category 3

GHS label elements

Hazard pictograms





Signal Word : Danger

Hazard Statements : H227 Combustible liquid.

H302 + H312 + H332 Harmful if swallowed, in contact with skin

or if inhaled.

H319 Causes serious eye irritation.



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

H336 May cause drowsiness or dizziness. H360D May damage the unborn child.

H371 May cause damage to organs (Nervous system, muscle).

Precautionary Statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P210 Keep away from heat, sparks, open flame and hot surfaces. No smoking.

P260 Do not breathe mist or vapors.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.

P302 + P352 + P312 IF ON SKIN: Wash with plenty of soap and water. Call a doctor if you feel unwell.

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P311 IF exposed or concerned: Call a doctor.

P308 + P313 IF exposed or concerned: Get medical attention.

P337 + P313 If eye irritation persists: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P403 + P235 Store in a well-ventilated place. Keep cool.

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Vapors may form explosive mixture with air.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
N,N-Dimethylformamide	68-12-2	>= 50 - < 70
Embutramide	15687-14-6	>= 20 - < 30



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Mebezonium iodide	7681-78-9	>= 5 - < 10
tetracaine hydrochloride	136-47-0	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

> If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person. Harmful if swallowed, in contact with skin or if inhaled.

Most important symptoms and effects, both acute and

delayed

Causes serious eye irritation.

May cause drowsiness or dizziness.

May damage the unborn child. May cause damage to organs.

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

High volume water jet

Specific hazards during fire

fighting

fire.

Flash back possible over considerable distance. Vapors may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Do not use a solid water stream as it may scatter and spread

Hazardous combustion prod: : Carbon oxides



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

ucts Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Remove all sources of ignition.
Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Non-sparking tools should be used.

Soak up with inert absorbent material.

Suppress (knock down) gases/vapors/mists with a water spray

jet.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapors.

Do not swallow. Do not get in eyes.



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Keep away from heat, hot surfaces, sparks, open flames and

other ignition sources. No smoking.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Keep away from heat and sources of ignition.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis	
•		(Form of	ters / Permissible		
		exposure)	concentration		
N,N-Dimethylformamide	68-12-2	TWA	5 ppm	ACGIH	
		TWA	10 ppm	NIOSH REL	
			30 mg/m ³		
		TWA	10 ppm	OSHA Z-1	
			30 mg/m ³		
Embutramide	15687-14-6	TWA	10 μg/m3 (OEB 3)	Internal	
		STEL	30 μg/m3	Internal	
		Wipe limit	100 μg/100 cm ²	Internal	
Mebezonium iodide	7681-78-9	TWA	1 μg/m3 (OEB 4)	Internal	
		STEL	3 μg/m3 (OEB 4)	Internal	
tetracaine hydrochloride	136-47-0	TWA	5 μg/m3 (OEB 4)	Internal	
	Further inform	Further information: DSEN, Skin			
		Wipe limit	50 μg/100 cm ²	Internal	

Biological occupational exposure limits

Components	CAS-No.	Control	Biological	Sam-	Permissible	Basis
		parameters	specimen	pling	concentra-	
				time	tion	
N,N-Dimethylformamide	68-12-2	Total N-	Urine	End of	30 mg/l	ACGIH
		Methylforma		shift (As	_	BEI



Embutramide / Mebezonium / Tetracaine Formulation

Version	Revision Date: 04/04/2023	SDS Number:	Date of last issue: 01/20/2023	
5.1		1714276-00019	Date of first issue: 05/25/2017	
		mide	soon as possible after	

mide		soon as possible after exposure ceases)		
N-Acetyl-S- (N- methylcarba moyl) cysteine	Urine		30 mg/l	ACGIH BEI

Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not

exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection

General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material Chemical-resistant gloves

Remarks Consider double gloving. Take note that the product is

flammable, which may impact the selection of hand

Wear safety glasses with side shields or goggles. Eye protection

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection Work uniform or laboratory coat.

> Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

If exposure to chemical is likely during typical use, provide Hygiene measures



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : 5-6

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : 178 °F / 81 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n- : No data available



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

octanol/water

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Combustible liquid.

Vapors may form explosive mixture with air. Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous d

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed, in contact with skin or if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,224 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 19.41 mg/l

Exposure time: 4 h
Test atmosphere: vapor
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: 1,942 mg/kg

Method: Calculation method



Embutramide / Mebezonium / Tetracaine Formulation

Version 5.1 Revision Date: 04/04/2023

SDS Number: 1714276-00019

Date of last issue: 01/20/2023 Date of first issue: 05/25/2017

Components:

N,N-Dimethylformamide:

Acute oral toxicity : LD50 (Rat): 3,010 mg/kg

Acute inhalation toxicity

Acute toxicity estimate: 11 mg/l

Exposure time: 4 h Test atmosphere: vapor Method: Expert judgment

Remarks: Based on national or regional regulation.

Acute dermal toxicity

Acute toxicity estimate: 1,100 mg/kg

Method: Expert judgment

Remarks: Based on national or regional regulation.

Embutramide:

Acute oral toxicity : LD50 (Rat): 1,550 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Dog): 31 mg/kg

Application Route: Intravenous

TDLo (Dog): 15.5 mg/kg Application Route: Intravenous

Symptoms: narcosis

LD50 (Horse): 20 mg/kg Application Route: Intravenous

LD50 (sheep): 80 mg/kg Application Route: Intravenous

LD50 (Pig): 100 mg/kg

Application Route: Intravenous

Mebezonium iodide:

Acute oral toxicity : LD50 (Rat, female): 200 - 300 mg/kg

Acute toxicity (other routes of :

administration)

LC50 (Dog): 15 mg/kg

Application Route: Intravenous

tetracaine hydrochloride:

Acute toxicity (other routes of :

administration)

LD50 (Rat): 6 mg/kg

Application Route: Intravenous

LD50 (Mouse): 6 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Components:

N,N-Dimethylformamide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

N,N-Dimethylformamide:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

N,N-Dimethylformamide:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact
Species : Mouse
Result : negative

tetracaine hydrochloride:

Routes of exposure : Dermal Result : Sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

N,N-Dimethylformamide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Rat

Application Route: inhalation (vapor)

Result: negative

Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

tetracaine hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: equivocal

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Rat Result: negative

Carcinogenicity

Not classified based on available information.

Components:

N,N-Dimethylformamide:

Species : Rat

Application Route : inhalation (vapor)

Exposure time : 2 Years

Method : OECD Test Guideline 451

Result : negative

Species : Mouse

Application Route : inhalation (vapor) Exposure time : 18 Months

Method : OECD Test Guideline 451

Result : negative

IARC Group 2A: Probably carcinogenic to humans

N,N-Dimethylformamide 68-12-2

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child.

Components:

N,N-Dimethylformamide:

Effects on fertility : Test Type: Two-generation study

Species: Mouse

Application Route: Ingestion

Result: negative

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Skin contact

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rabbit

Application Route: inhalation (vapor) Method: OECD Test Guideline 414

Result: positive

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Skin contact Method: OECD Test Guideline 414

Result: positive

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

tetracaine hydrochloride:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female Application Route: Subcutaneous Fertility: NOAEL: 7.5 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 5 mg/kg body weight

Result: No teratogenic effects.

Test Type: Development

Species: Rabbit

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: No teratogenic effects.



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

STOT-single exposure

May cause drowsiness or dizziness.

May cause damage to organs (Nervous system, muscle).

Components:

Embutramide:

Assessment : May cause drowsiness or dizziness.

Mebezonium iodide:

Target Organs : Nervous system, muscle
Assessment : May cause damage to organs.

tetracaine hydrochloride:

Target Organs : Central nervous system, Cardio-vascular system

Assessment : Causes damage to organs.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

N,N-Dimethylformamide:

Species : Rat

NOAEL : 238 mg/kg LOAEL : 475 mg/kg Application Route : Ingestion Exposure time : 28 Days

 Species
 : Rat

 NOAEL
 : 0.08 mg/l

 LOAEL
 : 0.3 mg/l

Application Route : inhalation (vapor)

Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Embutramide:

Inhalation : Target Organs: Central nervous system

Symptoms: Drowsiness, Central nervous system depression,

muscle weakness, Shortness of breath

Mebezonium iodide:

Inhalation : Symptoms: Weakness, Fatigue, Breathing difficulties

tetracaine hydrochloride:



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Inhalation : Target Organs: Cardio-vascular system

Target Organs: Central nervous system

Symptoms: Central nervous system depression, Dizziness,

Headache, hypotension, Vomiting

Skin contact : Symptoms: Redness, pruritis

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

N,N-Dimethylformamide:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 7,100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 13,100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): > 1,000

mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): > 1,000

mg/l

Exposure time: 72 h

Toxicity to daphnia and other

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 1,500 mg/l

Exposure time: 21 d

Embutramide:

Toxicity to fish : LC50 : 21 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 24 h

Test Type: Respiration inhibition of activated sludge

Method: OECD Test Guideline 209

Persistence and degradability

Components:

N,N-Dimethylformamide:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 100 % Exposure time: 21 d

Method: OECD Test Guideline 301E



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Bioaccumulative potential

Components:

N,N-Dimethylformamide:

Bioaccumulation Species: Cyprinus carpio (Carp)

> Bioconcentration factor (BCF): 0.3 - 1.2 Method: OECD Test Guideline 305C

Partition coefficient: n-

octanol/water

log Pow: -0.93

Remarks: Calculation

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging Empty containers should be taken to an approved waste

handling site for recycling or disposal.

Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number UN 3082

Proper shipping name Environmentally hazardous substance, liquid, n.o.s.

(N,N-Dimethylformamide)



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171
Marine pollutant : no

Remarks : THE ABOVE INFORMATION ONLY APPLIES TO PACKAGE

SIZES WHERE THE HAZARDOUS SUBSTANCE MEETS

THE REPORTABLE QUANTITY.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

Components	CAS-No.	Component RQ	Calculated product RQ
		(lbs)	(lbs)
N,N-Dimethylformamide	68-12-2	100	176

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Flammable (gases, aerosols, liquids, or solids)

Acute toxicity (any route of exposure)

Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

Serious eye damage or eye irritation

SARA 313 : The following components are subject to reporting levels

established by SARA Title III, Section 313:

N,N- 68-12-2 >= 50 - < 70 %

Dimethylforma-

mide

US State Regulations

Pennsylvania Right To Know

N,N-Dimethylformamide 68-12-2 Embutramide 15687-14-6 Water 7732-18-5 Mebezonium iodide 7681-78-9

California Prop. 65

WARNING: This product can expose you to chemicals including N,N-Dimethylformamide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

California List of Hazardous Substances

N,N-Dimethylformamide 68-12-2

California Permissible Exposure Limits for Chemical Contaminants

N,N-Dimethylformamide 68-12-2

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

Health 2 0 Instability

Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the



Embutramide / Mebezonium / Tetracaine Formulation

Version Revision Date: SDS Number: Date of last issue: 01/20/2023 5.1 04/04/2023 1714276-00019 Date of first issue: 05/25/2017

German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory: TECI - Thailand Existing Chemicals Inventory: TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 04/04/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8